Also known as: EC
Data center buildout faces growing legal and regulatory hurdles: environmental citizen suits, EU cloud rules that could exclude U.S. Big Tech from strategic tenders, and national security scrutiny of sovereign wealth fund investments. Local moratoria are spreading, and new EU rules would fast-track data centers while imposing non-price criteria.
Alnylam reported Q4 2025 adjusted EPS of $1.25, beating estimates, while revenue of $1.10 billion missed consensus despite 85% growth. Amvuttra sales surged 189% to $826.6 million. The stock fell 4.1% after the mixed results.
Novartis marks 30 years since its 1996 merger, citing advances in targeted therapy, cell therapy, gene therapy, and malaria. It also named a Levant Country President and won two clinical research awards in Saudi Arabia.
Lupin reported record Q3 FY2026 revenue of INR 7,168 crores and a 31.1% EBITDA margin, while preparing to launch a generic semaglutide and shifting focus to innovation. The company also secured US FDA approval for Pegfilgrastim and EU approval for ranibizumab biosimilar.
BioMarin reported Q2 2026 revenues of $990 million, up 20% Y/Y, and raised guidance. It filed an sNDA for VOXZOGO in hypochondroplasia and advanced BMN 333, BMN 820, and BMN 351.
Biotech companies posted Q2 2026 results: REGENXBIO's Duchenne trial met its primary endpoint, Compass Pathways' COMP360 NDA submission is on track for Q4, Puma raised full-year guidance on NERLYNX demand, and Evotec cut its 2026 outlook.
Insmed reported Q2 2026 revenues of $425.5M, with BRINSUPRI at $309.2M. It raised 2026 BRINSUPRI guidance to $1.25B-$1.40B and lifted peak revenue estimates for its lead programs to over $14B.
Moderna posted Q2 2026 revenue of $145 million and a GAAP net loss of $0.8 billion, while improving its 2026 spending outlook. Its norovirus candidate missed Phase 3 interim criteria, and mFLUSIVA faces an August 5 PDUFA decision.
Zemcelpro (dorocubicel) has achieved NUB Status 1 in Germany, enabling hospitals to seek temporary reimbursement, while Cordex Biologics expanded access to Asia and Argentina through a distribution deal with FarmaMondo. The cell therapy holds conditional EU authorization for certain blood cancers.
The European Commission granted marketing authorization to Sandoz for Bysumlog (insulin lispro) and Dazparda (insulin aspart), two biosimilar insulins developed by Gan & Lee Pharmaceuticals. A recent HHS analysis found most biosimilar markets become economically unviable after five competitors, prompting companies to diversify portfolios. Accord aims to bring 20 biosimilars to market by 2030.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07708649 |
Evaluating Practices That Foster Care Partnerships and Wellbeing Among Informal Carers and Long-term Care Workers |
NOT_YET_RECRUITING | NA |
| NCT07693894 |
DISARM Clinical Study B: Evaluation of Innovative Ovarian Cancer Biomarker Assays |
NOT_YET_RECRUITING | |
| NCT07681284 |
Noninvasive Brain Stimulation for Cervical Dystonia |
NOT_YET_RECRUITING | NA |
| NCT07636148 |
Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance |
NOT_YET_RECRUITING | |
| NCT07622537 |
Late Effects of Cancer Therapies on Gonadal Function, Fertility, Efficiency of Fertility Preservation Procedures and Pregnancy Outcomes |
NOT_YET_RECRUITING | |
| NCT07334912 |
AEF0217 in Participants With Down Syndrome |
RECRUITING | PHASE2 |
| NCT07129408 |
Epidemiological Study on the Prevalence of Mental Disorders in Slovakia |
COMPLETED | |
| NCT06897436 |
Characterization of Immune Cells and Their Secreted Cytokines in Endometriosis Patients |
NOT_YET_RECRUITING | |
| NCT06825156 |
Metabolic and Renal Outcomes in Cardiac Surgery Patients Receiving SGLT2 Inhibitors |
COMPLETED | PHASE4 |
| NCT06816147 |
HealthyW8_60+ Pilot |
RECRUITING | NA |
